RT Journal Article
SR Electronic
T1 Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22271099
DO 10.1101/2022.02.17.22271099
A1 Donnici, Claire
A1 Ilincic, Natasha
A1 Cao, Christian
A1 Zhang, Caseng
A1 Deveaux, Gabriel
A1 Clifton, David A.
A1 Buckeridge, David
A1 Bobrovitz, Niklas
A1 Arora, Rahul K.
YR 2022
UL http://medrxiv.org/content/early/2022/02/18/2022.02.17.22271099.abstract
AB Seroprevalence studies have been used throughout the COVID-19 pandemic to monitor infection and immunity. These studies are often reported in peer-reviewed journals, but the academic writing and publishing process can delay reporting and thereby public health action. Seroprevalence estimates have been reported faster in preprints and media, but with concerns about data quality. We aimed to (i) describe the timeliness of SARS-CoV-2 serosurveillance reporting by publication venue and study characteristics and (ii) identify relationships between timeliness, data validity, and representativeness to guide recommendations for serosurveillance efforts.We included seroprevalence studies published between January 1, 2020 and December 31, 2021 from the ongoing SeroTracker living systematic review. For each study, we calculated timeliness as the time elapsed between the end of sampling and the first public report. We evaluated data validity based on serological test performance and correction for sampling error, and representativeness based on use of a representative sample frame and adequate sample coverages. We examined how timeliness varied with study characteristics, representativeness, and data validity using univariate and multivariate Cox regression.We analyzed 1,844 studies. Median time to publication was 154 days (IQR 64-255), varying by publication venue (journal articles: 212 days, preprints: 101 days, institutional reports: 18 days, and media: 12 days). Multivariate analysis confirmed the relationship between timeliness and publication venue and showed that general population studies were published faster than special population or health care worker studies; there was no relationship between timeliness and study geographic scope, geographic region, representativeness, or serological test performance.Seroprevalence studies in peer-reviewed articles and preprints are published slowly, highlighting the limitations of using the academic literature to report seroprevalence during a health crisis. More timely reporting of seroprevalence estimates can improve their usefulness for surveillance, enabling more effective responses during health emergencies.Competing Interest StatementRahul K. Arora was previously a Technical Consultant for the Bill and Melinda Gates Foundation Strategic Investment Fund, is a minority shareholder of Alethea Medical, and was a former Senior Policy Advisor at Health Canada. David Buckeridge consults for the Public Health Agency of Canada and has participated with Medicago. David A. Clifton reports consulting fees from Sensyne Health, Oxford University Innovation, and BioBeats, each outside the submitted work. Each of these relationships is entirely unrelated to the present work. No other authors have conflicts of interest to report.Funding StatementThis work was funded by the Public Health Agency of Canada through Canada's COVID-19 Immunity Task Force. The funding source had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results. SeroTracker also receives funding from the World Health Organization Health Emergencies Programme, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. This manuscript does not necessarily reflect the views of the World Health Organization or any other funder. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors of this research article are contributors to SeroTracker, an interactive dashboard and data platform for SARS-CoV-2 seroprevalence. SeroTracker is a free, open-access tool that allows researchers and policymakers to visualize and analyze seroprevalence data. The data used in this research article was collected from the SeroTracker database which can be found and downloaded online (https://serotracker.com/en/Data). https://serotracker.com/en/Data RoBRisk of BiasJBIJoanna Briggs Institute critical appraisal toolFDAU.S. Food and Drug AdministrationEUAEmergency Use AuthorizationHRHazard RatioWHOWorld Health OrganizationCOVID-19Coronavirus Disease 2019